Published in Cancer Weekly, November 14th, 2006
Researchers in the United States conducted a study "to determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of tasidotin, a novel dolastatin analogue, when administered as a 30-minute i.v. infusion weekly for 3 weeks every 4 weeks. Thirty patients with advanced solid malignancies were treated with 82 courses at 6 dose levels ranging from 7.8 to 62.2 mg/m2 weekly, initially according to an accelerated dose-escalation scheme, which evolved into a Fibonacci scheme as a relevant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly